Acumen Pharmaceuticals, Inc.

NasdaqGS ABOS

Acumen Pharmaceuticals, Inc. Price to Book Ratio (P/B) on January 14, 2025: 0.38

Acumen Pharmaceuticals, Inc. Price to Book Ratio (P/B) is 0.38 on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Acumen Pharmaceuticals, Inc. 52-week high Price to Book Ratio (P/B) is 0.79 on November 08, 2024, which is 109.61% above the current Price to Book Ratio (P/B).
Acumen Pharmaceuticals, Inc. 52-week low Price to Book Ratio (P/B) is 0.38 on January 14, 2025, which is 0.00% below the current Price to Book Ratio (P/B).
Acumen Pharmaceuticals, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is 0.57.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqGS: ABOS

Acumen Pharmaceuticals, Inc.

CEO	Mr. Daniel J. O'Connell M.B.A.
IPO Date	July 1, 2021
Location	United States
Headquarters	427 Park Street
Employees	51
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Key trends

Past 5 years